Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

被引：34

作者：

Kuppen, Malou C. P. ^{[1
]}

Westgeest, Hans M. ^{[2
]}

van der Doelen, Maarten J. ^{[3
]}

van den Eertwegh, Alphonsus J. M. ^{[4
]}

Coenen, Jules L. L. M. ^{[5
]}

Aben, Katja K. H. ^{[6
,7
]}

van den Bergh, Alphons C. M. ^{[8
]}

Bergman, Andries M. ^{[9
]}

van den Bosch, Joan ^{[10
]}

Celik, Filiz ^{[11
]}

Hendriks, Mathijs P. ^{[12
]}

Lavalaye, Jules ^{[13
]}

van der Meer, Saskia ^{[14
]}

Polee, Marco B. ^{[15
]}

Somford, Diederik M. ^{[16
]}

van Oort, Inge M. ^{[17
]}

Uyl-de Groot, Carin A. ^{[1
]}

Gerritsen, Winald R. ^{[3
]}

机构：

[1] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Inst Med Technol Assessment, Rotterdam, Netherlands

[2] Amphia Hosp, Dept Internal Med, Breda, Netherlands

[3] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands

[4] Vrije Univ, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam UMC, Amsterdam, Netherlands

[5] Isala, Dept Oncol, Zwolle, Netherlands

[6] Radboud Univ Nijmegen, Dept Hlth Evidence, Med Ctr, Nijmegen, Netherlands

[7] Netherlands Comprehens Canc Org, Utrecht, Netherlands

[8] Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands

[9] Netherlands Canc Inst, Div Internal Med MOD & Oncogen, Antoni van Leeuwenhoek Hosp, Amsterdam, Netherlands

[10] Albert Schweitzer Ziekenhuis, Dept Internal Med, Dordrecht, Netherlands

[11] Deventer Hosp, Dept Nucl Med, Deventer, Netherlands

[12] Northwest Clin, Dept Internal Med, Alkmaar, Netherlands

[13] St Antonius Hosp, Dept Nucl Med, Nieuwegein, Netherlands

[14] Jeroen Bosch Hosp, Dept Urol, sHertogenbosch, Netherlands

[15] Med Ctr Leeuwarden, Dept Internal Med, Leeuwarden, Netherlands

[16] Canisius Wilhelmina Hosp, Dept Urol, Nijmegen, Netherlands

[17] Radboud Univ Nijmegen, Dept Urol, Med Ctr, Nijmegen, Netherlands

来源：

FUTURE ONCOLOGY | 2020年 / 16卷 / 19期

关键词：

metastatic castration-resistant prostate cancer; radium-223; real-world outcomes; sequencing; skeletal-related events; survival; BONE METASTASES; DOUBLE-BLIND; THERAPY; PHASE-3; TRIAL; RECOMMENDATIONS; EXPERIENCE; EFFICACY; EVENTS; CYCLES;

D O I：

10.2217/fon-2020-0039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line >= 3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line >= 3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

引用

页码：1371 / 1384

页数：14

共 32 条

[1] Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer [J].

Alva, Ajjai ;

Nordquist, Luke ;

Daignault, Stephanie ;

George, Saby ;

Ramos, Jorge ;

Albany, Costantine ;

Isharwal, Sudhir ;

McDonald, Matthew ;

Campbell, Gregory ;

Danchaivijitr, Pongwut ;

Yentz, Sarah ;

Anand, Aseem ;

Yu, Evan Y. .

PROSTATE, 2017, 77 (05) :479-488

[2] EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer [J].

Cornford, Philip ;

Bellmunt, Joaquim ;

Bolla, Michel ;

Briers, Erik ;

De Santis, Maria ;

Gross, Tobias ;

Henry, Ann M. ;

Joniau, Steven ;

Lam, Thomas B. ;

Mason, Malcolm D. ;

van der Poel, Henk G. ;

van der Kwast, Theo H. ;

Rouviere, Olivier ;

Wiegel, Thomas ;

Mottet, Nicolas .

EUROPEAN UROLOGY, 2017, 71 (04) :630-642

[3] Generalizability of cancer clinical trial results [J].

Elting, LS ;

Cooksley, C ;

Bekele, BN ;

Frumovitz, M ;

Avritscher, EBC ;

Sun, C ;

Bodurka, DC .

CANCER, 2006, 106 (11) :2452-2458

[4] Factors affecting 223Ra therapy: clinical experience after 532 cycles from a single institution [J].

Etchebehere, Elba C. ;

Milton, Denai R. ;

Araujo, John C. ;

Swanston, Nancy M. ;

Macapinlac, Homer A. ;

Rohren, Eric M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (01) :8-20

[5] Managing bone metastases and reducing skeletal related events in prostate cancer [J].

Gartrell, Benjamin A. ;

Saad, Fred .

NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (06) :335-345

[6] Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 [J].

Gillessen, S. ;

Omlin, A. ;

Attard, G. ;

de Bono, J. S. ;

Efstathiou, E. ;

Fizazi, K. ;

Halabi, S. ;

Nelson, P. S. ;

Sartor, O. ;

Smith, M. R. ;

Soule, H. R. ;

Akaza, H. ;

Beer, T. M. ;

Beltran, H. ;

Chinnaiyan, A. M. ;

Daugaard, G. ;

Davis, I. D. ;

De Santis, M. ;

Drake, C. G. ;

Eeles, R. A. ;

Fanti, S. ;

Gleave, M. E. ;

Heidenreich, A. ;

Hussain, M. ;

James, N. D. ;

Lecouvet, F. E. ;

Logothetis, C. J. ;

Mastris, K. ;

Nilsson, S. ;

Oh, W. K. ;

Olmos, D. ;

Padhani, A. R. ;

Parker, C. ;

Rubin, M. A. ;

Schalken, J. A. ;

Scher, H. I. ;

Sella, A. ;

Shore, N. D. ;

Small, E. J. ;

Sternberg, C. N. ;

Suzuki, H. ;

Sweeney, C. J. ;

Tannock, I. F. ;

Tombal, B. .

ANNALS OF ONCOLOGY, 2015, 26 (08) :1589-1604

[7] EMA guidance on radium-223 dichloride in prostate cancer [J].

Gourd, Elizabeth .

LANCET ONCOLOGY, 2018, 19 (04) :E190-E190

[8] The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer [J].

Heinrich, Daniel ;

Bektic, Jasmin ;

Bergman, Andries M. ;

Caffo, Orazio ;

Cathomas, Richard ;

Chi, Kim N. ;

Daugaard, Gedske ;

Keizman, Daniel ;

Kindblom, Jon ;

Kramer, Gero ;

Olmos, David ;

Omlin, Aurelius ;

Sridhar, Srikala S. ;

Tucci, Marcello ;

van Oort, Inge ;

Nilsson, Sten .

CLINICAL GENITOURINARY CANCER, 2018, 16 (01) :E223-E231

[9] Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial [J].

Hoskin, Peter ;

Sartor, Oliver ;

O'Sullivan, Joe M. ;

Johannessen, Dag Clement ;

Helle, Svein I. ;

Logue, John ;

Bottomley, David ;

Nilsson, Sten ;

Vogelzang, Nicholas J. ;

Fang, Fang ;

Wahba, Mona ;

Aksnes, Anne-Kirsti ;

Parker, Christopher .

LANCET ONCOLOGY, 2014, 15 (12) :1397-1406

[10] Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database [J].

Keizman, D. ;

Fosboel, M. O. ;

Reichegger, H. ;

Peer, A. ;

Rosenbaum, E. ;

Desax, M-C ;

Neiman, V. ;

Petersen, P. M. ;

Mueller, J. ;

Cathomas, R. ;

Gottfried, M. ;

Dresler, H. ;

Sarid, D. ;

Mermershtain, W. ;

Rouvinov, K. ;

Mortensen, J. ;

Gillessen, S. ;

Daugaard, G. ;

Omlin, A. .

PROSTATE CANCER AND PROSTATIC DISEASES, 2017, 20 (03) :289-293

← 1 2 3 4 →